- Bristol-Myers Squibb recently secured an expanded U.S. FDA approval for CAMZYOS for symptomatic obstructive hypertrophic cardiomyopathy across adults and eligible pediatric patients, and also reported Phase 3 EXCALIBER-RRMM data showing higher MRD negative complete response rates for ZENBEXUS based triplet therapy in relapsed or refractory multiple myeloma.
- These approvals and late stage oncology results highlight Bristol-Myers Squibb’s effort to convert targeted cardiology and multiple myeloma research into commercially relevant therapies that can help refresh its portfolio as older products face patent and competitive pressure.
- We will now see how this wider CAMZYOS indication shapes Bristol-Myers Squibb’s investment narrative around its growth portfolio and pipeline execution.
Bristol-Myers Squibb Investment Narrative Recap
To stay comfortable holding Bristol-Myers Squibb, you need to believe its newer therapies can steadily reshape the product mix as older blockbusters move toward patent pressure and pricing headwinds. The expanded CAMZYOS label and positive ZENBEXUS triplet data both relate directly to that shift in cardiology and multiple myeloma. These milestones do not remove the patent cliff risk around Eliquis, but they give more substance to the growth portfolio story that already accounts for nearly 60% of sales.
In the near term, the key operational catalyst is execution on recent and upcoming launches, from CAMZYOS and ZENBEXUS to Sotyktu in new immune driven indications. Uptake, payer access and safety management will influence whether earnings can hold up as revenue is expected by analysts to drift lower over the next few years. The biggest risk remains that this cluster of therapies proves too narrow or encounters safety or regulatory setbacks, which could widen the revenue gap as established drugs mature.
The EXCALIBER RRMM data for ZENBEXUS combined with daratumumab and dexamethasone is the clearest link to the broader Bristol-Myers Squibb story right now. A 41.1% MRD negative complete response rate versus 20.7% for the comparator triplet in the primary efficacy population suggests this asset may deepen its role in relapsed or refractory multiple myeloma, subject to longer term outcomes and safety follow up.
For you as an investor, the relevance is straightforward. Multiple myeloma is a core franchise where Bristol-Myers Squibb needs fresh contributors as Revlimid and Pomalyst feel more pressure. EXCALIBER RRMM outcomes, together with continued evidence generation for ZENBEXUS under its accelerated approval, sit on the short list of data and adoption catalysts that can either narrow or widen the gap analysts currently expect between today’s earnings and their projected declines over the next three years.
Bristol-Myers Squibb's analyst narrative points to revenues of US$40.1b and earnings of US$8.3b by 2029, based on a forecast yearly revenue decline of 6.6% and an earnings decrease of about US$1.0b from earnings today of US$9.3b.
Uncover why Bristol-Myers Squibb's fair value indicates a 12% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
Some of the most optimistic Bristol-Myers Squibb analysts were already building a different story around CELMoDs like ZENBEXUS. They were pencilling in 2029 revenue of about US$42.8b and earnings of US$10.6b, compared with the baseline US$40.1b and US$8.3b. You can now ask whether CAMZYOS and the EXCALIBER RRMM result eventually push expectations closer to that upper range. The forecasts were set before this news, so use them as bookends and explore how your own view might shift as the cardiology and multiple myeloma data filters into updated models.
Explore 3 other Bristol-Myers Squibb fair value estimates, including one that suggests there could be as much as 103% upside from the current price!
Form Your Own Verdict
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Bristol-Myers Squibb. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.
Looking For More Investment Ideas Beyond Bristol-Myers Squibb?
If you want to put Bristol-Myers Squibb in context and pressure test your thesis, it helps to line it up against other opportunities with different risk and income profiles. The Simply Wall St Screener gives you a quick way to compare this pharmaceutical heavyweight with focused lists of companies that share specific traits you might be targeting in your portfolio.
- For investors hunting for underpriced quality, review companies filtered for both fundamentals and valuation through the 29 high quality undervalued stocks.
- If capital preservation sits higher on your priority list, consider stocks highlighted for resilience and downside protection in the 31 resilient stocks with low risk scores.
- For those building a watchlist of financially robust businesses, scan the list of solid balance sheet and fundamentals (25 results) and see which tickers pass the balance sheet stress test.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com